Cargando…

Fulvestrant as a reference antiestrogen and estrogen receptor (ER) degrader in preclinical studies: treatment dosage, efficacy, and implications on development of new ER-targeting agents

Detalles Bibliográficos
Autor principal:	Wang, Guangdi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508469/ https://www.ncbi.nlm.nih.gov/pubmed/32968620 http://dx.doi.org/10.21037/tcr-20-2166

Ejemplares similares

Estrogen Receptor-Alpha 36 Mediates Mitogenic Antiestrogen Signaling in ER-Negative Breast Cancer Cells
por: Zhang, XinTian, et al.
Publicado: (2012)

The Antiestrogens Tamoxifen and Fulvestrant Abolish Estrogenic Impacts of 17α-ethinylestradiol on Male Calling Behavior of Xenopus laevis
por: Hoffmann, Frauke, et al.
Publicado: (2012)

G0S2 promotes antiestrogenic and pro-migratory responses in ER+ and ER- breast cancer cells
por: Corbet, Andrea K., et al.
Publicado: (2023)

HAS2-Ezrin-ER axis plays a role in acquired antiestrogen resistance of ER-positive breast cancer
por: Sun, Xiaodan, et al.
Publicado: (2022)

Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
por: Hopcroft, Lorna, et al.
Publicado: (2023)

A Closer Look at Estrogen Receptor Mutations in Breast Cancer and Their Implications for Estrogen and Antiestrogen Responses
por: Clusan, Léa, et al.
Publicado: (2021)

Andrographolide Inhibits ER-Positive Breast Cancer Growth and Enhances Fulvestrant Efficacy via ROS-FOXM1-ER-α Axis
por: Xu, Tong, et al.
Publicado: (2022)

Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy
por: Wardell, Suzanne E., et al.
Publicado: (2019)

Estrogenic or antiestrogenic therapies for multiple myeloma?
por: Sola, Brigitte, et al.
Publicado: (2007)

The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance
por: Nardone, Agostina, et al.
Publicado: (2018)

Concomitant fulvestrant with reirradiation for unresectable locoregional recurrent estrogen receptor positive (ER+) breast cancer: A case report and narrative review
por: Ding, Jingxian, et al.
Publicado: (2020)

Forskolin Stimulates Estrogen Receptor (ER) α Transcriptional Activity and Protects ER from Degradation by Distinct Mechanisms
por: Tsai, Houng-Wei, et al.
Publicado: (2022)

Correction to: Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy
por: Wardell, Suzanne E., et al.
Publicado: (2019)

Rethinking the combination treatment of fulvestrant and anastrozole for metastatic breast cancer: an integrated reanalysis of aromatase–estrogen receptor axis
por: Huang, Xing
Publicado: (2019)

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
por: Hopcroft, Lorna, et al.
Publicado: (2023)

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
por: Hopcroft, Lorna, et al.
Publicado: (2023)

ZEB1 induces ER-α promoter hypermethylation and confers antiestrogen resistance in breast cancer
por: Zhang, Jianbo, et al.
Publicado: (2017)

Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER(+) Breast Cancer
por: Servetto, Alberto, et al.
Publicado: (2021)

Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer
por: Yi, Jun Ho, et al.
Publicado: (2014)

Respective role of membrane and nuclear estrogen receptor (ER) α in the mandible of growing mice: Implications for ERα modulation
por: Vinel, Alexia, et al.
Publicado: (2018)

Males Require Estrogen Signaling Too: Sexual Dimorphism in the Regulation of Glucose Homeostasis by Nuclear ERα
por: Alejandro, Emilyn Uy
Publicado: (2019)

Response of Estrogen Receptor-Positive Breast Cancer Tumorspheres to Antiestrogen Treatments
por: Ao, Ada, et al.
Publicado: (2011)

Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ
por: Mishra, Ameet K., et al.
Publicado: (2016)

ERβ1 Sensitizes and ERβ2 Desensitizes ERα-Positive Breast Cancer Cells to the Inhibitory Effects of Tamoxifen, Fulvestrant and Their Combination with All-Trans Retinoic Acid
por: Meligova, Aggeliki K., et al.
Publicado: (2023)

The Co-Expression of Estrogen Receptors ERα, ERβ, and GPER in Endometrial Cancer
por: Hojnik, Marko, et al.
Publicado: (2023)

Targeting estrogen to kill ER-positive and ER-negative breast cancer
por: Jordan, VC
Publicado: (2005)

Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer
por: Cameron, D A, et al.
Publicado: (2008)

Role of SUMOylation in differential ERα transcriptional repression by tamoxifen and fulvestrant in breast cancer cells
por: Traboulsi, Tatiana, et al.
Publicado: (2018)

Phase II trial of fulvestrant plus enzalutamide in ER+/HER2− advanced breast cancer
por: Elias, Anthony D., et al.
Publicado: (2023)

Functions and physiological roles of two types of estrogen receptors, ERα and ERβ, identified by estrogen receptor knockout mouse
por: Lee, Hye-Rim, et al.
Publicado: (2012)

A role for estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) in collagen biosynthesis in mouse skin
por: Markiewicz, Margaret, et al.
Publicado: (2012)

Clinical implication of low estrogen receptor (ER-low) expression in breast cancer
por: Reinert, Tomás, et al.
Publicado: (2022)

ER–mitochondria contacts: Actin dynamics at the ER control mitochondrial fission via calcium release
por: Steffen, Janos, et al.
Publicado: (2018)

Screening for estrogenic and antiestrogenic activities of plants growing in Egypt and Thailand
por: El-Halawany, Ali M., et al.
Publicado: (2011)

Estrogenic/antiestrogenic activity of selected selective serotonin reuptake inhibitors
por: POP, ANCA, et al.
Publicado: (2015)

The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppresses proliferative recovery in ER-positive breast cancer
por: Finnegan, Ryan M., et al.
Publicado: (2023)

Molecular conformation, receptor binding, and hormone action of natural and synthetic estrogens and antiestrogens.
por: Duax, W L, et al.
Publicado: (1985)

Revisiting Fulvestrant Dosing in Uncertain Economic Times
por: Patel, Amol, et al.
Publicado: (2021)

Estrogen Signaling in ERα-Negative Breast Cancer: ERβ and GPER
por: Girgert, Rainer, et al.
Publicado: (2019)

Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer
por: O’Leary, Ben, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nn8v02jj09of78i3jnpk7r6i6b